DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the CIPLA LTD (CIPLA) share price today?

CIPLA LTD (CIPLA) is trading at ₹1,418.7 on the NSE, down 0.76% on the day. Source: DocStoX.

What is the PE ratio of CIPLA LTD?

CIPLA LTD has a price-to-earnings (PE) ratio of 29.5 in the Healthcare sector.

What is the market capitalisation of CIPLA LTD?

CIPLA LTD has a market capitalisation of approximately ₹1,14,589 crore.

CIPLA LTD

F&O

CIPLA·NSE·Healthcare

₹1,418.70▼ -10.80 (-0.76%)

Healthcare · Pharmaceuticals

A steady, established business

NIFTY 50NIFTY 100NIFTY 200

Day₹1404.00

₹1434.00

52W₹1166

₹167350%

Open

₹1429.50

High

₹1434.00

Low

₹1404.00

Prev Close

₹1429.50

Volume

6.07L

VWAP

₹1415.61

Snapshot

Key fundamentals

Market Cap

₹1.15L Cr

P/E Ratio

29.54Fair

P/B Ratio

3.42

EPS

₹48.02

Book Value

₹426.00

ROE

11.60%Average

ROCE

15.00%Decent

Dividend Yield

0.90%

Debt / Equity

0.02Low

Face Value

₹2.00

52W High

₹1673.00

52W Low

₹1165.70

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹482

▼ 66.1%downside

Trading at ₹1,419 — 66% above our estimate

BearFair valueBull

₹409₹482₹678

/100

Business quality — Watch the fundamentals

Growth 36Profitability 49Efficiency 18Valuation 75

Plain English

Our view

A steady, established business
Virtually debt-free balance sheet
Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

12% ROE fading to 12% over ~3 yrs, on ₹426 book

₹427

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹678

Analyst target

No analyst coverage

—

Blended fair value₹482

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet

Bear case

Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

29.5Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

11.6%Average

Above 15% is considered healthy for Indian equities

ROCE

15.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.02Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹1.15L Cr

P/B

3.42

EPS

₹48.02

Div Yield

0.90%

What changed

Recent changes

Foreign investors-1.4% stake last quarter
Domestic institutions+1.3% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 29.5×

Growth

Steady

+7% rev CAGR

Profitability

Modest

11.6% ROE

Financial health

Rock solid

D/E 0.02

Momentum

N/A

No technicals

Today

Trading activity

Delivery %49.2%

Turnover₹8593.56L Cr

Trades49,038

VWAP₹1415.61

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+7.4%

+8.0%

10Y

+7.4%

Profit

+10.9%

+10.1%

10Y

+10.8%

EPS

+11.4%

+10.0%

10Y

+11.0%

Profile

Pros

Company is almost debt free.
Company has been maintaining a healthy dividend payout of 25.7%

Watch-outs

Cons

The company has delivered a poor sales growth of 8.01% over past five years.
Promoter holding has decreased over last 3 years: -4.34%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 1.38 pts; domestic institutions added 1.26 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

29%

Promoter

Promoters

29.2%0.00

Public

16.3%+0.14

FII / FPI

22.6%-1.38

DII

31.7%+1.26

Total shareholders

5,84,217+43,696 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter29.22%

FII22.55%

DII31.71%

Public16.26%

Others0.26%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1935, Cipla Ltd is in the business of manufacturing, developing, and marketing a wide range of branded and generic formulations and APIs[1]

F&O

CIPLA LTD valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

CIPLA LTD peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

SUN PHARMACEUTICAL IND L DIVI S LABORATORIES LTD TORRENT PHARMACEUTICALS L APOLLO HOSPITALS ENTER. L ZYDUS LIFESCIENCES LTD LUPIN LIMITED MAX HEALTHCARE INS LTD MANKIND PHARMA LIMITED DR. REDDY S LABORATORIES AUROBINDO PHARMA LTD LAURUS LABS LIMITED FORTIS HEALTHCARE LTD

Compare CIPLA LTD with peers

CIPLA LTD vs SUN PHARMACEUTICAL IND L CIPLA LTD vs DIVI S LABORATORIES LTD CIPLA LTD vs TORRENT PHARMACEUTICALS L CIPLA LTD vs APOLLO HOSPITALS ENTER. L CIPLA LTD vs ZYDUS LIFESCIENCES LTD CIPLA LTD vs LUPIN LIMITED

CIPLA LTD

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

F&O

CIPLA LTD valuation & research

CIPLA LTD peers in Healthcare

Compare CIPLA LTD with peers

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Ownership breakdown

Ownership over time

Frequently asked questions